The IHC results demonstrated a dramatically decreased in APOL1 expression levels in FSGS patients compared with healthy control, and even lower levels were observed in glomeruli of FSGS patients with APOL1 mutation. Here, APOL1 is linked to focal segmental glomerulosclerosis.